Home » Newsletters » BioWorld Science

BioWorld Science

June 5, 2012

View Archived Issues

Abbott presents new serotonin 5-HT6 receptor modulators

Co-clinical study method identifies mutations limiting lung cancer treatment efficacy

Tyrosine-protein kinase SYK inhibitor has beneficial effects on asthma

Preliminary phase I results presented on AZD-2014

Olodaterol shows efficacy in asthma trials

Clinical data show long-term effects of lebrikizumab and the role of periostin

Novel GPR17 receptor modulators reported by Italian group

Theravance discloses novel candidate hepatitis C therapies

GlaxoSmithKline discovers new LDH-A inhibitors

Novel treatments for IBD prepared by Spanish team

Researchers at Marine Polymer Technologies patent new potential melanoma vaccines

Astellas and Drais partner on another IBS drug candidate

OTSA-101 receives E.U. orphan drug status

GE Healthcare and Affibody collaborate on HER2-specific PET imaging agent

Baxter and Chatham enter collaboration on hemophilia B gene therapy development

Takeda expands its position in gout market

First-in-human data presented on novel selective Notch pathway inhibitor

AFFiRiS launches first-ever clinical study of vaccine candidate for Parkinson's disease

Cleveland BioLabs reports survival results with CBLB-502

Emergent BioSolutions obtains BARDA funding for BioThrax

Evotec/Boehringer Ingelheim alliance reaches milestone

ThromboGenics and BioInvent to regain global rights to PlGF-directed mAb

Phase IIb data on anticoagulant lead to decision to stop its development

Genmab and Novartis enter bispecific antibody collaboration

Dainippon Sumitomo Pharma and Shionogi to copromote combination hypertension drug in Japan

Janssen files NDA for canagliflozin

Astellas and Ambit begin phase IIb quizartinib monotherapy study in relapsed/refractory AML

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 16, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...